Valiant Laboratories Ltd

AI
Valiant Laborato Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Valiant Laboratories Ltd

₹ 121 -1.99%
04 Nov - close price
valiantlabs.in BSE: 543998 NSE: VALIANTLAB
About

Incorporated in 1980, Valiant Laboratories
Ltd manufactures and deals in Pharmaceuticals and speciality chemicals[1]

Key Points

Business Overview:[1][2]
VLL is in the active pharmaceutical ingredient manufacturing business. It manufactures finished dosage forms of paracetamol API viz. Tablets, Capsules, and Other medications. Paracetamol API is a key ingredient used to treat a variety of conditions including Headache, Arthritis, Muscle Aches, Toothache, Backache, Cold, and Fever

Website BSE NSE - BE
  • Market Cap ₹ 656 Cr.
  • Current Price ₹ 121
  • High / Low ₹ 141 / 49.5
  • Stock P/E 45.3
  • Book Value ₹ 60.9
  • Dividend Yield 0.00 %
  • ROCE 2.36 %
  • ROE 1.75 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company is expected to give good quarter

Cons

  • The company has delivered a poor sales growth of 3.54% over past five years.
  • Company has a low return on equity of -0.40% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
59.55 40.52 30.58 18.88 21.48 35.23 57.77 51.01 45.99 54.74 65.30 73.42 72.43
60.94 46.83 35.11 21.27 28.21 34.61 53.94 48.65 45.93 54.50 60.79 60.92 70.29
Operating Profit -1.39 -6.31 -4.53 -2.39 -6.73 0.62 3.83 2.36 0.06 0.24 4.51 12.50 2.14
OPM % -2.33% -15.57% -14.81% -12.66% -31.33% 1.76% 6.63% 4.63% 0.13% 0.44% 6.91% 17.03% 2.95%
2.96 1.78 2.50 2.17 1.93 0.67 0.65 0.67 0.85 0.61 0.77 0.85 0.41
Interest 0.02 0.02 0.02 0.05 0.01 0.06 0.05 0.07 0.14 0.03 0.02 0.08 0.09
Depreciation 0.49 0.49 0.50 0.50 0.51 0.51 0.51 0.51 0.51 0.72 0.52 0.55 0.57
Profit before tax 1.06 -5.04 -2.55 -0.77 -5.32 0.72 3.92 2.45 0.26 0.10 4.74 12.72 1.89
Tax % 25.47% -30.75% -52.16% 31.17% 12.41% -122.22% 17.60% 25.71% 34.62% 80.00% 25.32% 25.55% 23.28%
0.79 -3.50 -1.22 -1.01 -5.98 1.60 3.24 1.82 0.17 0.03 3.53 9.48 1.45
EPS in Rs 0.23 -0.75 -0.26 -0.22 -1.28 0.34 0.69 0.39 0.03 0.01 0.65 1.75 0.27
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
182 292 334 182 133 217 266
132 249 299 190 138 210 246
Operating Profit 50 42 35 -8 -5 7 19
OPM % 27% 15% 11% -4.6% -3.5% 3.3% 7%
1 2 5 10 5 3 3
Interest 2 0 0 0 0 0 0
Depreciation 3 2 2 2 2 2 2
Profit before tax 47 42 38 -1 -1 8 19
Tax % 35% 34% 24% -145% 49% 26%
31 28 29 0 -2 6 14
EPS in Rs 7.86 8.26 0.07 -0.46 1.02 2.68
Dividend Payout % 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 4%
3 Years: -13%
TTM: 40%
Compounded Profit Growth
10 Years: %
5 Years: -31%
3 Years: -45%
TTM: 112%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: -11%
1 Year: 45%
Return on Equity
10 Years: %
5 Years: 6%
3 Years: 0%
Last Year: 2%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 10 16 33 43 43 54 54
Reserves 78 55 68 193 191 265 276
1 61 60 60 60 1 1
17 49 52 28 23 65 49
Total Liabilities 106 182 213 325 317 386 381
20 22 30 32 30 30 31
CWIP 0 1 0 0 0 0 1
Investments 0 0 34 119 165 191 198
87 158 149 174 122 165 152
Total Assets 106 182 213 325 317 386 381

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
9 2 23 49 -22 -14
-17 -12 -21 -183 25 -8
11 6 -2 136 -0 20
Net Cash Flow 4 -4 0 2 3 -2
Free Cash Flow 7 -5 16 45 -22 -15
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 51% 40% 91% -569% 537% -178%

Ratios

Standalone / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 85 139 97 92 197 140
Inventory Days 18 25 17 22 12 45
Days Payable 37 72 62 54 61 118
Cash Conversion Cycle 66 91 52 60 149 67
Working Capital Days 102 109 106 97 194 158
ROCE % 38% 26% -2% -1% 2%

Insights

In beta
Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Paracetamol Capacity Utilisation
% of installed capacity

Log in to view insights

Please log in to see hidden values.

Login
Revenue from Top 5 Customers
INR million
Average Realization per MT (Paracetamol)
INR per MT
Domestic Revenue Share
% of total revenue
Installed Paracetamol Manufacturing Capacity (Tarapur)
MT per month
Paracetamol Sales Volume
MT
Permanent Employees
count

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94%
7.08% 3.48% 1.89% 0.00% 0.00% 0.64% 0.63% 0.02% 0.01% 0.20% 0.00% 0.07%
0.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.46% 0.00% 0.00% 0.00% 0.00% 0.08%
17.54% 21.58% 23.18% 25.06% 25.06% 24.42% 23.97% 25.05% 25.05% 24.87% 25.06% 24.91%
No. of Shareholders 15,82114,91414,24915,18915,69215,03614,43215,07514,91014,65714,34114,618

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings